RTP Mobile Logo
Novel and Emerging Therapeutic Strategies in the Management of Hematologic Disorder-Related Anemia (Video Program)
Released July 2019

Featuring perspectives from Drs Rami Komrokji and Maria-Domenica Cappellini. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    OVERVIEW OF ACTIVITY
    Several hematologic disorders are associated with anemia that can be linked to ineffective erythropoiesis. This occurs when the marrow cannot maintain adequate red blood cell production or produces defective or immature cells that are incapable of proper functioning. Myelodysplastic syndromes (MDS), myeloproliferative neoplasms and beta thalassemia are examples of disorders often associated with moderate to severe anemia. Few treatment options are available for inherited and acquired disorders of erythropoiesis, and despite significant research gains many uncertainties and clinical challenges persist in regard to the management of related anemia. Thus it is imperative that the oncology community have access to up-to-date medical education programs designed to comprehensively address current therapeutic approaches and promising research that can facilitate effective clinical decision-making.

    To bridge the gap between research and patient care, this program features one-on-one discussions with leading hematology-oncology investigators. Upon completion of this CME activity, medical oncologists and hematologists should be able to formulate an up-to-date and more complete approach to the care of patients with anemia associated with hematologic disorders.

    LEARNING OBJECTIVES

    • Understand the causes and consequences of blood disorder-associated anemia, and use this information to refine disease management and supportive care of patients.
    • Describe the biologic rationale for and mechanism of action of erythroid maturation agents (EMAs) in the treatment of anemia secondary to select hematologic disorders, including MDS, beta thalassemia and myelofibrosis.
    • Appraise emerging clinical data with the EMA luspatercept in preparation for its potential availability for the management of beta thalassemia and/or low-risk MDS.
    • Recognize the importance of screening for iron overload in transfusion-dependent patients, and develop a systematic approach for initiating and delivering iron chelation therapy.
    • Analyze the biologic basis for and early research data with gene-based therapies for beta thalassemia.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Rami Komrokji, MD
    Senior Member
    Section Head, Leukemia and MDS
    Vice Chair, Department of Malignant Hematology
    H Lee Moffitt Cancer Center
    Professor of Oncologic Sciences
    University of South Florida
    Tampa, Florida

    Consulting Agreements: Celgene Corporation, Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc, Novartis; Speakers Bureau: Jazz Pharmaceuticals Inc, Novartis.

    Maria-Domenica Cappellini, MD
    Professor of Internal Medicine
    University of Milan
    Fondazione IRCCS Ca’ Granda Ospedale Policlinico
    Milan, Italy

    Advisory Committee: Celgene Corporation, Genzyme Corporation, Novartis, Sanofi Genzyme, Vifor Pharma.

    EDITORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Celgene Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: July 2019
    Expiration date: July 2020

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Interview with Rami Komrokji, MD

Interview with Maria-Domenica Cappellini, MD

Select Publications